A trial of targeted drugs for bile duct cancer and gallbladder cancer (SAFIR-ABC10)
This trial is looking at targeted drugs for bile duct cancer and gallbladder cancer that has spread to another part of the body or has come back after treatment
Cancer of the small sack by the liver that stores bile before it is released into the gut to help digest fats. Connected to the gut by the bile duct.
This trial is looking at targeted drugs for bile duct cancer and gallbladder cancer that has spread to another part of the body or has come back after treatment
This trial is looking at aspirin to try and reduce the risk of cancer for people with primary sclerosing cholangitis and inflammatory bowel disease.
This study is looking at changes to the liver and the immune system which could help diagnose liver cancer at an early stage.
This study is looking at using a blood sample to detect small pieces of DNA released into the blood by cancer cells.
This study is looking at whether the number and types of bacteria that live naturally in our bowel affects how well the treatment for biliary cancer works.
Gallbladder cancer mortality rates are projected to fall by 2% in the UK between 2023-2025 and 2038-2040.
There could be around around 820 deaths of gallbladder cancer every year in the UK by 2038-2040, projections suggest.
Gallbladder cancer incidence rates are projected to rise by 47% in the UK between 2023-2025 and 2038-2040.
There could be around 3,100 new cases of gallbladder cancer every year in the UK by 2038-2040, projections suggest.
This trial was done to find out if oxaliplatin and 5FU is useful for people with advanced biliary tract cancer who have already had chemotherapy.
This trial was looking at trastuzumab deruxtecan for cancers that had a high number of HER2 receptors (HER2).
This study looked at a blood test called a multi cancer early detection (MCED) test. It is also called the Galleri test.